BrainStorm Announces Second U.S. Manufacturing Site For NurOwn® Production

Date Published07/02/2018
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name BrainStorm Cell Therapeutics Inc.
Parent companyBrainStorm Cell Therapeutics Inc.
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Domestically, the work will be done:In-house
Country(ies) from which reshored:Israel
City reshored to:Boston
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredPharmaceuticals
What domestic positive factors made reshoring more attractive?Eco-system synergies, Under-utilized capacity
Find Reshoring Articles